Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimemazine add-on treatment for children with ADHD and atopic disease
NL-OMON24270Not yet recruiting
- Sponsor
- Medisch Centrum Leeuwarden
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of alimemazine in attention deficit hyperactivity disorder (ADHD), atopic dermatitis (AD), asthma and 1 more (2 arms), sponsored by Medisch Centrum Leeuwarden. Primary endpoints: Parent-rated ADHD improvement on SNAP-IV, Asthma symptom control and 2 more. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
alimemazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)atopic dermatitis (AD)asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NL-OMON24270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24270.